Ongoing But Closed To Enrollment

An Open label study of the Pharmacokinetics of BG00012 (DMF) and the Effects of DMF on Exploratory Biomarkers in Subjects with Secondary Progressive Multiple Sclerosis (SPMS)
Sponsor: MS Center of Northeastern NY

The purpose of this study is to explore whether DMF (Dimethyl Fumarate) or MMF (monomethylfumarate) its main bioactive metabolite, is capable of entering the central nervous system in SPMS patients that are being treated with Tecfidera®.  Oxidative Stress and other exploratory biomarkers in CSF and blood may also be tested. PK samples (pharmacokinetics) or the amount of study drug in  blood) will be tested to compare with PK samples, the amount of study drug, in  spinal fluid (CSF).
Click here for more information from ClinicalTrials website:


SWITCH STUDY
Sponsor: MS Center of Northeastern NY

TITLE: Safety and Effectiveness of Switching Relapsing MS Patients Treated with Natalizumab (Tysabri) at Risk for PML to Teriflunomide (Aubagio).
Click here for more information on ClinicalTrials.gov 


    1. SYNERGY STUDY
      Sponsor: Biogen

  1. TITLE: A randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 (Anti-LINGO-1) in Subjects with Relapsing When Used Concurrently with Avonex.
  2. Click here for more information on ClinicalTrials.gov

  3. DAC HYP STUDY
    Sponsor: Biogen

  4. TITLE: Multi-center, Double-blind, Randomized, Parallel-group, Mono-therapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon  1a) in Patients With Relapsing-Remitting Multiple Sclerosis
  5. Click here for more information on ClinicalTrials.gov 

    • ASCEND STUDY
    • Sponsor: Biogen
    1. OCRELIZUMAB OPERA STUDY
    2. Sponsor: Hoffmann-La Roche
  1. TITLE: A Randomized, Double-Blind, Double Dummy, Parallel group study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif ) in patients with Relapsing Multiple Sclerosis
  2. Click here for more information from ClinicalTrials.gov

  3. Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
    Sponsor: Genzyme

  4. TITLE: A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS).
  5. Click here for more information on ClinicalTrials.gov

  6. Safety of Xeomin for lower limb spasticity in Multiple Sclerosis patients.
    Sponsor: MS Center of Northeastern NY

  7. TITLE: A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis
  8. Click here for more information on ClinicalTrials.gov